About James Momtazee
James Momtazee is a director at Roivant Sciences.
Form D filings name James Momtazee as a director at Kriya Therapeutics.
James Momtazee reports to the SEC as a director, officer or major shareholder of 8 public companies, including BridgeBio Pharma (BBIO), Montes Archimedes Acquisition (MAAC) and PRA Health Sciences (PRAH).
James Momtazee first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name James Momtazee in the role, so the role may have started earlier or lasted longer.
RL
Roivant Sciences Ltd.
Director
2021 – 2026 · Public company (ROIV)
BI
BridgeBio Pharma, Inc.
Director and 10% owner
2019 – 2026 · Public company (BBIO)
MC
Montes Archimedes Acquisition Corp
Chief Executive Officer and director
2020 – 2021 · Public company (MAAC)
PI
PRA Health Sciences, Inc.
Director
2014 – 2021 · Public company (PRAH)
EI
Entellus Medical Inc.
Director
2017 – 2018 · Public company (ENTL)
JP
Jazz Pharmaceuticals plc
Director
2007 – 2013 · Public company (JAZZ)
HI
HCA Healthcare, Inc.
Reporting person
2008 · Public company (HCA)
AI
Alliance HealthCare Services, Inc
Director
2006 – 2007 · Public company (AIQ)
Key Colleagues at Startups
The people James Momtazee works with at each company, as listed on that company's latest Form D.
Kriya Therapeutics, Inc. · Form D/A, Sep 10, 2025
NV
Neelaksh Varshney
Director
MS
Michele Stone
Executive officer
IO
Ilan Oren
Director
SR
Saira Ramasastry
Director
RG
Ryan Gallagher
Director
KM
Keith Manchester
Director
KE
Katherine Eade
Executive officer
AR
Akshay Rai
Director
SR
Shankar Ramaswamy
Chief Executive Officer and director
CH
Curt Herberts
Executive officer
BP
Britt Petty
Executive officer
RJ
Roger Jeffs
Director
BF
Brian Furmanski
Executive officer
TG
Trit Garg
Director